Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 19, 2017
What is the competitive landscape for MYLAN PHARMS INC, and when can generic versions of MYLAN PHARMS INC drugs launch?
MYLAN PHARMS INC has two hundred and thirty-eight approved drugs.| Patents: | 12 |
| Tradenames: | 195 |
| Ingredients: | 185 |
| NDAs: | 238 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
ketoconazole | Foam | 2% | EXTINA | 7/30/2009 |
betamethasone valerate | Foam | 0.12% | LUXIQ | 8/10/2007 |
clobetasol propionate | Topical Foam | 0.05% | OLUX | 6/27/2005 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,629,128 | Vitamin formulation | ► Subscribe | |||||||||||||||||||||||||||
| 9,486,394 | Pharmaceutical foam | ► Subscribe | |||||||||||||||||||||||||||
| 7,749,488 | Pharmaceutical foam | ► Subscribe | |||||||||||||||||||||||||||
| 5,075,445 | Guanine derivatives | ► Subscribe | |||||||||||||||||||||||||||
| 5,886,215 | 2-acetoxymethyl-4-halo-butyl-1-yl acetates | ► Subscribe | |||||||||||||||||||||||||||
| 5,684,153 | Process for the preparation of purine derivatives | ► Subscribe | |||||||||||||||||||||||||||
| 8,586,066 | Topical antifungal composition | ► Subscribe | |||||||||||||||||||||||||||
| 5,250,688 | Purine derivatives | ► Subscribe | |||||||||||||||||||||||||||
| 6,126,920 | Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition | ► Subscribe | |||||||||||||||||||||||||||
| 8,298,515 | Vitamin formulation | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spain | 2277394 | ► Subscribe | |||||||||||||||||||||||||||
| New Zealand | 302727 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2001520184 | ► Subscribe | |||||||||||||||||||||||||||
| Hungary | 9900801 | ► Subscribe | |||||||||||||||||||||||||||
| Finland | 923371 | ► Subscribe | |||||||||||||||||||||||||||
| Taiwan | 307687 | ► Subscribe | |||||||||||||||||||||||||||
| Hong Kong | 218996 | ► Subscribe | |||||||||||||||||||||||||||
| Spain | 2299258 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | H0625241 | ► Subscribe | |||||||||||||||||||||||||||
| China | 1053547 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014026,C1506211 | Lithuania | ► Subscribe | PRODUCT NAME: DAPAGLIFLOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116 | ||||||||||||||||||||||||||
| C0009 | Belgium | ► Subscribe | PRODUCT NAME: COLFOSCERIL PALMITAS (DIPALMITOYLPHOSPHATIDYLCHOLINE) (DPPC); NAT REG.: 251 IS 142 F 12; FIRST REG.: GB PL 0003/0283 19901214 | ||||||||||||||||||||||||||
| C0048 | France | ► Subscribe | PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707 | ||||||||||||||||||||||||||
| C0036 | Belgium | ► Subscribe | PRODUCT NAME: CHLORHYDRATE DE ROPINIROLE (=ROPINIROLE); NAT. REGISTRATION NO/DATE: 981 IS 120 F 3 19970414; FIRST REGISTRATION: GB PL 10592/0085 19960702 | ||||||||||||||||||||||||||
| 00214 | Netherlands | ► Subscribe | PRODUCT NAME: ERLOTINIB, DESGEWENST IN DE; REGISTRATION NO/DATE: 57266 01,..02,..03EU/1/05/311/001...003 20050321 | ||||||||||||||||||||||||||
| 2004004,C0717738 | Lithuania | ► Subscribe | PRODUCT NAME: LINEZOLIDUM ((S)-N-((3-(3-FLUOR-4-(4-MORFOLINIL)FENIL)-2-OKSO--5-OKSAZOLIDINIL)METIL)-ACETAMIDAS); REGISTRATION NO/DATE: 02/8199/2 20030313 | ||||||||||||||||||||||||||
| 00528 | Netherlands | ► Subscribe | PRODUCT NAME: COMBINATIE VAN ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN HYDROCHLOORTHIAZIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; NATL. REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION: CH 61678 01-05 20110705 | ||||||||||||||||||||||||||
| C/GB09/032 | United Kingdom | ► Subscribe | PRODUCT NAME: PRASUGREL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/08/503/001 20090225; UK EU/1/08/503/002 20090225; UK EU/1/08/503/003 20090225; UK EU/1/08/503/004 20090225 | ||||||||||||||||||||||||||
| 00486 | Netherlands | ► Subscribe | PRODUCT NAME: COMBINATIE VAN OLMESARTANMEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, AMLODIPINEBESYLAAT AND HYDROCHLOORTHIAZIDE; NATL REGISTRATION NO/DATE: RVG 106667, RVG 106671-74, RVG 106682-86 20101221; FIRST REGISTRATION: DE 79810.00.00-79814.00.00 20101216 | ||||||||||||||||||||||||||
| 2014 00038 | Denmark | ► Subscribe | PRODUCT NAME: TRAVOPROST; REG. NO/DATE: EU/1/01/199/001-002 20011127 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,662 others who get our Drug Patent Expiration Alerts:
